{"entity":{"id":"nct04041310","kind":"trial","name":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Nouscom SRL, active and no longer recruiting.","summary":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors is a phase 1/2 interventional study registered as NCT04041310 by Nouscom SRL, with 115 participants enrolled, started 2019-10-21 and due to reach its primary completion in 2026-10-30. Interventions recorded: GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D and MVA-209-FSP, RP2D.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04041310","url":"https://clinicaltrials.gov/study/NCT04041310"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["nouscom","merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04041310","phase":"1/2","setting":"A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","sponsor":"Nouscom SRL","enrolled":115,"outcomes":[]},"route":"/trials/nct04041310/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"},{"id":"nouscom","kind":"company","name":"Nouscom","route":"/companies/nouscom/"}]}}